Compare MINISO Group Holding Ltd (MNSO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? MINISO Group Holding Ltd trades at $10.36 (market cap $2.89B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: MINISO Group Holding Ltd is far larger — about 3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and MINISO Group Holding Ltd pays a 6.71% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 25 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MNSO | MRVI | |
|---|---|---|
Market Cap | $2.89B | $972.90M |
Volume | 1,658,211 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $9.00 |
52-Week Low | $8.60 | $2.83 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $3.76B | $1.08B |
Dividend Yield | 6.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.92, up 1.95% with a bullish technical signal despite mixed earnings history. The company shows solid fundamentals with $21.44B revenue, 5.35% net margin, and attractive valuation ratios including P/E of 16.11 and P/S of 0.86. Recent CFO share purchases and analyst optimism (60% buy rating) support positive sentiment, though earnings misses in three of the last four quarters highlight execution risks amid competitive retail pressures.
The outlook remains cautiously optimistic given MNSO's valuation appeal and growth potential, but investors should monitor earnings consistency and overseas margin pressures. Key opportunities include domestic expansion and operational optimization, while risks involve volatile quarterly performance and intense retail competition.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
